UK Bans Valproate Use Without Pregnancy Prevention Program; First In EU To Do So?
Executive Summary
Following the endorsement of EU-wide restrictions on the safe use of anti-epilepsy drug valproate, the UK appears to be the first member state to put in place a pregnancy prevention program to reduce the number of pregnancies exposed to valproate medicines to an absolute minimum and make sure all women and girls of childbearing potential are aware of the risks.
You may also be interested in...
EMA Probe Into Paternal Valproate Exposure Risk Continues After ‘Errors’ Found In Study
Initial results from a study indicate that children born to men taking valproate medicines are at an increased risk of having neurodevelopmental disorders, but “important limitations” and “errors” with the data highlight the need for further analysis.
Scathing Report On UK Health Care System Failings Calls For Big Changes
A damning UK report makes uncomfortable reading about how thousands of women suffered avoidable harm from the anti-epileptic drug sodium valproate and two other medical interventions and how safety concerns raised were dismissed, overlooked and ignored.
Sanofi Faces Charges Over Valproate Birth Defects
In a case that has parallels with that of Servier’s diabetes drug Mediator, Sanofi has been indicted over its alleged lack of transparency over the birth defects associated with use of its valproate drug in pregnant women.